Alphabet's AI drug discovery unit Isomorphic Labs closed a $5 billion round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new backer alongside Alphabet and all existing investors. It is the company's second billion-dollar raise in six months, following $2.1 billion in May 2026, and the capital will advance its in-house IsoDDE platform and push its drug pipeline toward clinical trials.
AI Drug Discovery
AI 制药
Paradigm using machine learning to predict molecular structure, binding affinity and druggability to accelerate preclinical R&D.
Curated Intelligence
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, has closed a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and all existing backers participating. Building on AlphaFold, its simulation-model engine has produced positive preclinical results in oncology and immunology and underpins deals with Eli Lilly, Novartis and Johnson & Johnson; the new capital is aimed at moving candidates into clinical trials.
Isomorphic Labs, Alphabet's AI-driven drug discovery unit led by Nobel laureate Demis Hassabis, has closed a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with a16z joining as a new investor and Alphabet continuing to commit heavily. The proceeds will fund foundational simulation models, expand internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.
Gu Quanquan's five-month-old startup Geodesic Intelligence is publicly challenging Anthropic CEO Dario Amodei's ten-year timeline, claiming AI can compress drug discovery cycles to four years. If borne out, the claim would mark a shift of AI for Science from assistive tooling to a core engine reshaping pharma R&D.
Anthropic CEO Dario Amodei predicted AI will make cancer, Alzheimer's and heart disease history within a decade, echoing optimistic timelines from Musk and Hassabis. Drug-industry executives and physicians pushed back, arguing AI can only speed early molecule screening and cannot bypass the 10-12 year clinical trial and regulatory pipeline; as of 2026 no AI-designed drug has reached full clinical use.
Google DeepMind, Meta, and Isomorphic Labs jointly invested $300 million into Mark Zuckerberg's nonprofit Biohub to build large-scale AI datasets for digital biological research. This funding is part of a broader $1.8 billion initiative, signaling deep collaboration among tech giants on AI-driven biomedical infrastructure.